Diabetic Vision Loss Medication May Promote Return to DrivingDiabetic Vision Loss Medication May Promote Return to Driving
After a year of treatment with the drug ranibizumab (Lucentis), some people with vision loss due to diabetes regain their confidence to drive and have vision good enough to do so, according to a new study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - November 30, 2015 Category: Opthalmology Tags: Diabetes & Endocrinology News Source Type: news
Diabetic vision loss medication may promote return to driving
(Reuters Health) - After a year of treatment with the drug ranibizumab (Lucentis), some people with vision loss due to diabetes regain their confidence to drive and have vision good enough to do so, according to a new study. (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
New treatment options, better hope of preventing vision loss from diabetes
This National Diabetes Month, there is some good news for people with eye complications from diabetes. A network of researchers has found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. The researchers say this is the first major advance in therapy in 40 years. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 19, 2015 Category: Science Source Type: news
New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes
This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. The researchers, part of the Diabetic Retinopathy Clinical Research Network, say this is the first major advance in therapy in 40 years. (Source: News from NEI)
Source: News from NEI - November 19, 2015 Category: Opthalmology Authors: Jason Source Type: news
Squalamine Boosts Anti-VEGF Effect in Macular DegenerationSqualamine Boosts Anti-VEGF Effect in Macular Degeneration
The addition of squalamine lactate to ranibizumab did not reduce the number of injections in patients with neovascular age-related macular degeneration, but it did improve visual acuity. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - November 17, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Lucentis Found Effective for Diabetic Retinopathy (CME/CE)
(MedPage Today) -- Could be first new treatment for diabetic retinopathy in many years (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 17, 2015 Category: Cardiology Source Type: news
Ranibizumab found effective against diabetic retinopathy
(Johns Hopkins Medicine) In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab -- a drug most commonly used to treat retinal swelling in people with diabetes -- is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2015 Category: Global & Universal Source Type: news
Lucentis effective for proliferative diabetic retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 16, 2015 Category: American Health Source Type: news
Drug Lucentis May Fight Diabetic Eye Disease
Title: Drug Lucentis May Fight Diabetic Eye DiseaseCategory: Health NewsCreated: 11/13/2015 12:00:00 AMLast Editorial Review: 11/16/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 16, 2015 Category: Endocrinology Source Type: news
Ranibizumab Deemed Major Advance for Diabetic Retinopathy Ranibizumab Deemed Major Advance for Diabetic Retinopathy
Ranibizumab was noninferior to panretinal photocoagulation for visual acuity in patients with proliferative diabetic retinopathy, according to 2-year results of the Protocol S Study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Injection instead of laser may be viable treatment option for diabetic retinopathy
Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at two years, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 14, 2015 Category: Science Source Type: news
Drug Lucentis May Fight Diabetic Eye Disease
Government-funded study finds injected medicine beats laser therapy for form of retinopathy (Source: WebMD Health)
Source: WebMD Health - November 14, 2015 Category: Consumer Health News Source Type: news
Diabetic blindness could be reversed with eye injection
Injecting the drug ranibizumab into the eyes of diabetics improved their sight and prevented further deterioration (Source: Telegraph Health)
Source: Telegraph Health - November 14, 2015 Category: Consumer Health News Tags: injection ranibizumab blind drugs blindness diabetes Source Type: news
Drug Lucentis May Fight Diabetic Eye Disease
Government-funded study finds injected medicine beats laser therapy for form of retinopathy
Source: HealthDay
Related MedlinePlus Pages: Diabetic Eye Problems, Eye Diseases, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 14, 2015 Category: Consumer Health News Source Type: news
Lucentis Effective for Proliferative Diabetic Retinopathy
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s. The findings demonstrate the first major therapy advance in nearly 40 years.
Language
English (Source: News from NEI)
Source: News from NEI - November 11, 2015 Category: Opthalmology Authors: Jason Source Type: news
